NASDAQ:CTIC - CTI BioPharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.48 -0.02 (-1.33 %)
(As of 12/12/2018 04:00 PM ET)
Previous Close$1.50
Today's Range$1.48 - $1.59
52-Week Range$1.48 - $5.36
Volume141,578 shs
Average Volume410,342 shs
Market Capitalization$87.56 million
P/E Ratio-1.19
Dividend YieldN/A
Beta-0.43
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. The company's product candidate in pipeline includes tosedostat, a novel oral, once-daily aminopeptidase inhibitor for patients with acute myeloid leukemia. It has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; Teva Pharmaceutical Industries Ltd; University of Vermont; S*BIO Pte Ltd; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTIC
Previous SymbolNASDAQ:CTICD
CUSIPN/A
Phone206-282-7100

Debt

Debt-to-Equity Ratio0.20
Current Ratio3.58
Quick Ratio3.58

Price-To-Earnings

Trailing P/E Ratio-1.19
Forward P/E Ratio-1.90
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.15 million
Price / Sales3.41
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.35 per share
Price / Book4.23

Profitability

EPS (Most Recent Fiscal Year)($1.24)
Net Income$-40,670,000.00
Net Margins-361.97%
Return on Equity-85.84%
Return on Assets-48.99%

Miscellaneous

Employees57
Outstanding Shares57,990,000
Market Cap$87.56 million
OptionableOptionable

CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

CTI BioPharma's stock reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp (NASDAQ:CTIC) posted its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.06. The biopharmaceutical company earned $0.72 million during the quarter, compared to analysts' expectations of $0.60 million. CTI BioPharma had a negative net margin of 361.97% and a negative return on equity of 85.84%. View CTI BioPharma's Earnings History.

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for CTI BioPharma.

What price target have analysts set for CTIC?

4 brokers have issued 12 month target prices for CTI BioPharma's stock. Their predictions range from $4.00 to $10.00. On average, they expect CTI BioPharma's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 339.2% from the stock's current price. View Analyst Price Targets for CTI BioPharma.

What is the consensus analysts' recommendation for CTI BioPharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CTI BioPharma.

Has CTI BioPharma been receiving favorable news coverage?

Headlines about CTIC stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CTI BioPharma earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future.

Who are some of CTI BioPharma's key competitors?

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the folowing people:
  • Dr. Adam R. Craig, Pres, CEO & Director (Age 52)
  • Dr. Jack W. Singer, Co-Founder & Consultant (Age 75)
  • Mr. David H. Kirske, Exec. VP & CFO (Age 64)
  • Mr. Bruce J. Seeley, COO, Exec. VP & Sec. (Age 54)
  • Mr. Ed Bell, Sr. Director of Investor Relations

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (9.14%), Stonepine Capital Management LLC (7.15%), BlackRock Inc. (4.97%), Opaleye Management Inc. (2.67%), FMR LLC (1.64%) and JPMorgan Chase & Co. (0.98%). Company insiders that own CTI BioPharma stock include Bvf Partners L P/Il, Richard L Love and Value Fund L P Biotechnology. View Institutional Ownership Trends for CTI BioPharma.

Which institutional investors are selling CTI BioPharma stock?

CTIC stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and AXA. View Insider Buying and Selling for CTI BioPharma.

Which institutional investors are buying CTI BioPharma stock?

CTIC stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Stonepine Capital Management LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Algert Global LLC, Stonepine Capital Management LLC and BlackRock Inc.. Company insiders that have bought CTI BioPharma stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for CTI BioPharma.

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $1.48.

How big of a company is CTI BioPharma?

CTI BioPharma has a market capitalization of $87.56 million and generates $25.15 million in revenue each year. The biopharmaceutical company earns $-40,670,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. CTI BioPharma employs 57 workers across the globe.

What is CTI BioPharma's official website?

The official website for CTI BioPharma is http://www.ctibiopharma.com.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]


MarketBeat Community Rating for CTI BioPharma (NASDAQ CTIC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  418
MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote "Outperform" if you believe CTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Featured Article: Put Option

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel